SUPPLEMENTAL MATERIAL

Table S1. Different characteristics of patients with and those without SCN5A mutations.

|			SCN5A (+) n = 16	SCN5A (-) n = 123	*p* value
Clinical parameters	Male	(patients)	16 (100%)	120 (98%)	1.0000
	Age	(years)	40.9 ± 17.4	45.7 ± 11.6	0.3032
	Symptomatic patients	(patients)	10 (63%)	49 (40%)	0.0948
	Syncope	(patients)	8 (50%)	41 (33%)	
	VT/VF	(patients)	2 (13%)	8 (7%)	0.2973
	Family history of SD	(patients)	7 (44%)	44 (36%)	0.5904
	SCN5A mutation	(patients)	16 (100%)	0	-
	VT/VF during follow-up	(patients)	5 (31%)	23 (19%)	0.3197
ECG parameters	Spontaneous type 1 ECG	(patients)	13 (81%)	96 (78%)	1.0000
	PQ interval (ms)	II Pre SCB	195 ± 29	180 ± 27	0.0247
		Post SCB	259 ± 39	231 ± 36	0.0037
	QRS width (ms)	V1 Pre SCB	113 ± 24	107 ± 14	0.8274
		Post SCB	163 ± 42	132 ± 20	0.0012
		V2 Pre SCB	114 ± 23	108 ± 15	0.4853
		Post SCB	167 ± 43	135 ± 20	0.0015
	ST level (mV)	V1 Pre SCB	0.182 ± 0.103	0.161 ± 0.104	0.7426
		Post SCB	0.210 ± 0.131	0.287 ± 0.177	0.0905
		V2 Pre SCB	0.291 ± 0.152	0.290 ± 0.177	0.7024
		Post SCB	0.482 ± 0.290	0.593 ± 0.276	0.1359
	QTc interval (ms)	V5 Pre SCB	386 ± 30	392 ± 30	0.6927
		Post SCB	451 ± 51	432 ± 34	0.1757
	Drug-induced VA (n)	overall	4 (25%)	15 (12%)	0.2386
		PVCs	1 (6%)	9 (7%)	1.0000
		VTs	3 (19%)	6 (5%)	0.0713

* p value: comparison of ECG parameters before and after the SCB test.

SCB: sodium channel blocker, SD: sudden death, VTA: ventricular tachyarrhythmia, VT/VF: ventricular tachycardia/ventricular fibrillation.

Figure S1. Receiver operating curves (ROC) for fatal arrhythmic events during follow-up. ROC curves of PQ interval (**A**), ST level in lead V1 (**B**) and QRS interval in lead V1 (**C**) after administration of pilsicainide.

Post PQ (ms)	Sensitivity (%)	Specificity (%)
230	74	57
235	65	66
240	55	70

Post V1ST (mV)	Sensitivity (%)	Specificity (%)
0.29	68	66
0.3	68	69
0.32	61	72

Post V1QRS (ms)	Sensitivity (%)	Specificity (%)
130	74	53
132	74	63
134	61	68